// App-Quantinova.ai

605 : Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Researchers

Presenter

  • Arivarasan Karunamurthy

Principal Investigators

  • Robert Morrison

  • Yulong Bai

  • Jie Sun

  • Hong Wang

  • Douglas Hartman

  • Julie Stein

  • Christopher Deitrick

  • Riyue Bao

  • Jagjit Singh

  • Quanquan Ding

  • Wentao Gao

  • Drew Hurd

  • Ornella Pagliano

  • Amy Rose

  • Yana Najjar

  • Jason Luke

  • David Mauro

  • Arthur Krieg

  • James Wooldridge

  • Dmitri Bobilev

  • John Kirkwood

  • Janis Taube

  • Hyun Jung Park

  • Hassane Zarour

  • Diwakar Davar

Medical Centers

  • Ra Pharmaceuticals Cambridge MA United States

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

  • John Hopkins University, Baltimore, Maryland, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved